Loading people...
Cassidy Blundell is a Partner at Mission BioCapital based in Cambridge, Massachusetts. She holds a PhD in Bioengineering from the University of Pennsylvania and a BS in Biomedical Engineering from Boston University. Blundell joined Mission BioCapital as an analyst in 2018 before advancing to her current leadership role, where she recently helped deploy capital from the firm's $143.75 million Fund VI. In her capacity as an early-stage therapeutics investor, she serves as a Board Director for several biotechnology startups, including Progentos Therapeutics, Mediar Therapeutics, Volnay Therapeutics, and ARase Therapeutics. She also holds a Board Observer seat at Vaxess Technologies and previously gained investment experience as a Senior Associate at Vida Ventures. Her current focus centers on early-stage therapeutic company creation and providing interim operational leadership for portfolio companies developing novel fibrotic disease treatments.
Cassidy Blundell is a Principal at Mission BioCapital, a prominent venture capital firm known for its deep expertise in the life sciences sector. Her role involves identifying, evaluating, and supporting promising early-stage companies that are at the forefront of biotechnological and healthcare innovation. She plays a vital part in the firm's mission to invest in transformative science and technology that can significantly impact human health.
At Mission BioCapital, Cassidy Blundell's investment focus spans a wide array of areas within biotechnology and life sciences. This includes novel therapeutics, diagnostics, medical devices, and other healthcare solutions. She is particularly interested in companies that are developing disruptive technologies and platforms with the potential to address critical unmet medical needs. Her analytical approach helps pinpoint opportunities where scientific rigor meets market potential, ensuring that Mission BioCapital's portfolio comprises companies poised for substantial growth and impact. The firm typically invests in seed to Series B rounds, partnering with founders to build robust companies from the ground up.
Cassidy Blundell brings a strong foundation in both science and finance to her role. While specific details of her pre-Mission BioCapital career are not provided, professionals in her position typically possess a blend of scientific acumen, often with advanced degrees in biological sciences, and extensive experience in venture capital, corporate development, or investment banking within the healthcare sector. This dual expertise allows her to thoroughly assess the scientific validity and commercial viability of potential investments, making her an invaluable asset to the Mission BioCapital team and the companies they support. Her background likely includes rigorous analytical roles, contributing to her ability to navigate the complex landscape of early-stage life science investing.
Mission BioCapital is renowned for its hands-on approach, providing not just capital but also strategic guidance and operational support to its portfolio companies. Cassidy Blundell embodies this philosophy, working closely with entrepreneurs to help them overcome challenges, refine their strategies, and accelerate their path to market. The firm's commitment to fostering innovation is evident in its diverse portfolio, which includes companies developing cutting-edge treatments for cancer, rare diseases, neurological disorders, and infectious diseases. Through her work, Cassidy helps ensure that these promising ventures receive the resources and mentorship needed to translate scientific discoveries into tangible patient benefits. Her dedication to the life sciences investment ecosystem underscores Mission BioCapital's reputation as a key player in advancing healthcare innovation.
Cassidy Blundell is a Principal at Mission BioCapital, a venture capital firm specializing in life science investments. She is responsible for identifying and supporting early-stage biotechnology and healthcare companies.
Cassidy Blundell invests in early-stage biotechnology and life science companies. Her focus areas include novel therapeutics, diagnostics, medical devices, and other healthcare solutions with the potential to address unmet medical needs.
Cassidy Blundell works at Mission BioCapital, a leading venture capital firm dedicated to investing in and nurturing innovative companies within the life sciences sector.
